WallStSmart

Viking Holdings Ltd (VIK)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Viking Holdings Ltd generates 102% more annual revenue ($6.50B vs $3.22B). VIK leads profitability with a 17.6% profit margin vs 16.9%. VIK trades at a lower P/E of 32.7x. WST earns a higher WallStSmart Score of 67/100 (B-).

VIK

Strong Buy

66

out of 100

Grade: B-

Growth: 9.3Profit: 8.5Value: 4.7Quality: 4.3
Piotroski: 6/9Altman Z: 0.16

WST

Strong Buy

67

out of 100

Grade: B-

Growth: 7.3Profit: 8.0Value: 2.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for VIK.

WSTSignificantly Overvalued (-32.4%)

Margin of Safety

-32.4%

Fair Value

$185.95

Current Price

$325.92

$139.97 premium

UndervaluedFair: $185.95Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

VIK4 strengths · Avg: 9.0/10
Return on EquityProfitability
254.5%10/10

Every $100 of equity generates 255 in profit

EPS GrowthGrowth
226.6%10/10

Earnings expanding 226.6% YoY

Operating MarginProfitability
20.9%8/10

Strong operational efficiency at 20.9%

Revenue GrowthGrowth
27.8%8/10

Revenue surging 27.8% year-over-year

WST4 strengths · Avg: 9.0/10
EPS GrowthGrowth
56.1%10/10

Earnings expanding 56.1% YoY

Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.7%8/10

Strong operational efficiency at 21.7%

Revenue GrowthGrowth
21.0%8/10

Revenue surging 21.0% year-over-year

Areas to Watch

VIK3 concerns · Avg: 2.7/10
P/E RatioValuation
32.7x4/10

Premium valuation, high expectations priced in

Price/BookValuation
33.7x2/10

Trading at 33.7x book value

Altman Z-ScoreHealth
0.162/10

Distress zone — elevated risk

WST2 concerns · Avg: 2.0/10
PEG RatioValuation
2.892/10

Expensive relative to growth rate

P/E RatioValuation
41.8x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : VIK

The strongest argument for VIK centers on Return on Equity, EPS Growth, Operating Margin. Profitability is solid with margins at 17.6% and operating margin at 20.9%. Revenue growth of 27.8% demonstrates continued momentum.

Bull Case : WST

The strongest argument for WST centers on EPS Growth, Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.9% and operating margin at 21.7%. Revenue growth of 21.0% demonstrates continued momentum.

Bear Case : VIK

The primary concerns for VIK are P/E Ratio, Price/Book, Altman Z-Score.

Bear Case : WST

The primary concerns for WST are PEG Ratio, P/E Ratio. A P/E of 41.8x leaves little room for execution misses.

Key Dynamics to Monitor

VIK carries more volatility with a beta of 1.57 — expect wider price swings.

VIK is growing revenue faster at 27.8% — sustainability is the question.

VIK generates stronger free cash flow (675M), providing more financial flexibility.

Monitor TRAVEL SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

WST scores higher overall (67/100 vs 66/100), backed by strong 16.9% margins and 21.0% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Viking Holdings Ltd

CONSUMER CYCLICAL · TRAVEL SERVICES · USA

Viking Holdings Ltd engages in the passenger shipping and other forms of passenger transport in North America, the United Kingdom, and internationally. The company is headquartered in Pembroke, Bermuda.

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?